Bristol-Myers Squibb's Opdivo approved to treat blood cancer in EU

Bristol-Myers Squibb's drug Opdivo (nivolumab) has been approved for use in the European Union (EU) to treat classical Hodgkin lymphoma (cHL), a type of blood cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news